Axela is now offering an expanded line of products for multiplexing DNA, RNA and protein biomarker analysis to accelerate the introduction of diagnostic products.
Through the acquisition of Xceed Molecular, Axela is now able to offer the Ziplex system for gene-expression analysis, the Breast Cancer Prognostic Assay and the Colon Cancer Xpress chip.
Axela said it is able to provide clinical researchers a suite of products for enhanced analysis of proteins, pathogens, DNA and RNA to speed validation and clinical application of biomarkers.
The Ziplex system is an integrated system for automated gene-expression analysis.
It standardises and streamlines gene-expression services, while saving staff time and ensuring reliable results.
The system's Flow-Thru Chip technology quickly performs highly multiplexed assays with reproducibility.
It also consumes less sample and lowers costs.
Advances in automation, array format, parallel sample processing and analytics minimise complexity, user interaction and variability between users and sites.
Axela's Dotlab system offers a real-time, user-configurable multiplex assay.
The expanded company's combined suite of Panelplus tools and services are said to enable new approaches to biomarker validation, disease diagnosis and personalised medicine.
Axela will also continue the validation programme for Xceed's Breast Cancer Prognostic Assay, a gene-expression signature designed to predict risk of recurrence for breast cancer patients.
Axela will now be headquartered at Xceed's former facility in Toronto.
